SANTA MONICA, Calif.--(BUSINESS WIRE)--Today, GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., announced the availability of new affordability programs for menopause hormone therapies by Pfizer. Through the reach and scale of the GoodRx platform, these programs are broadening access and affordability of crucial medications for women..

加利福尼亚州圣莫尼卡（商业新闻短讯）——今天，美国领先的处方储蓄平台GoodRx（纳斯达克：GDRX）宣布，辉瑞公司推出了更年期激素治疗新的可负担性计划。通过GoodRx平台的覆盖范围和规模，这些计划正在扩大女性获得关键药物的渠道和负担能力。。

New research from GoodRx shows menopause medications have increased in list price by 58% since 2014. And according to a recent study, people who’ve been diagnosed as menopausal spend 45% more on healthcare costs to treat their symptoms each year than those who are not menopausal. Similarly, women are often faced with a “pink tax,” which represents a significant inequality in healthcare where women pay more for their medical needs.

GoodRx的最新研究表明，自2014年以来，更年期药物的标价增加了58%。根据最近的一项研究，被诊断为更年期的人每年在治疗症状方面的医疗费用比未更年期的人多45%。同样，女性经常面临“粉红色税”，这意味着医疗保健方面的严重不平等，女性为其医疗需求支付更多费用。

That is why GoodRx is working to make necessary menopause treatments more affordable and accessible for women who are faced with limited coverage and high out-of-pocket costs..

这就是为什么GoodRx正在努力使必要的更年期治疗更加实惠，并且对于那些面临有限覆盖率和高额自付费用的女性来说更容易获得。。

“Americans are paying more than ever for medications, a challenge that disproportionately affects women,” said Dorothy Gemmell, Chief Commercial Officer at GoodRx. “At GoodRx, we’re not just making strides towards affordability, but also championing the needs of women from perimenopause through menopause to improve their lives.

GoodRx首席商务官多萝西·杰梅尔（DorothyGemmell）表示：“美国人为药物支付的费用比以往任何时候都要高，这一挑战对女性的影响不成比例。”。“在GoodRx，我们不仅在负担能力方面取得了进展，而且还支持从围绝经期到更年期的女性改善生活的需求。

We are committed to lowering prescription medications costs and shining a light on menopause – a complex condition that can impact a woman's physical, emotional, mental, and social well-being and having treatment options is critical.”.

我们致力于降低处方药成本，并为更年期（更年期是一种复杂的疾病，会影响女性的身体，情绪，心理和社会福祉）提供启示，拥有治疗选择至关重要。”。

Now, eligible patients with a valid prescription can find low cash prices for brand-name menopause hormone therapies in the range of $99-$249 at more than 70,000 pharmacies nationwide exclusively via GoodRx.

现在，拥有有效处方的合格患者可以通过GoodRx在全国70000多家药店找到99-249美元的品牌更年期激素疗法的低现金价格。

For those looking for more affordable ways to access other menopause medications, GoodRx has also created a Savings Guide for Popular Menopause Treatments.

对于那些寻找更实惠的方式获得其他更年期药物的人，GoodRx还为流行的更年期治疗创建了一个储蓄指南。

“I’m thrilled to see GoodRx tackle a major hurdle in women’s healthcare – the accessibility of menopause treatments,” said Dr. Lisa Larkin, Immediate Past President of The Menopause Society. “Menopause is a natural phase of a woman’s life that deserves attention and care, not something to be ignored or stigmatized.

更年期协会前任主席丽莎·拉金（LisaLarkin）博士说：“我很高兴看到古德克斯（GoodRx）解决了女性医疗保健的一个主要障碍——更年期治疗的可及性。”。“更年期是女性生命的自然阶段，值得关注和照顾，而不是被忽视或污名化。

By reducing the cost barrier and spotlighting the importance of menopausal health, this initiative directly supports women’s health, their ability to enjoy their lives and encourages a broader dialogue about comprehensive care for all stages of a woman’s life. Efforts like this one are exactly what’s needed to improve health outcomes for women everywhere.”.

通过减少成本障碍和强调更年期健康的重要性，这项倡议直接支持妇女的健康，她们享受生活的能力，并鼓励就妇女生命各个阶段的全面护理进行更广泛的对话。像这样的努力正是改善世界各地女性健康状况所需要的。”。

GoodRx works with over 150 brands across pharmaceutical manufacturers, medical device companies and OTC medicines to surface their savings and patient support programs directly with high-intent audiences via the GoodRx platform. The company recently announced a partnership with ARS Pharmaceuticals to offer neffy at an exclusive low discounted cash price in retail pharmacies across the U.S.

GoodRx与制药商、医疗器械公司和OTC药品的150多个品牌合作，通过GoodRx平台直接向高意向受众展示其储蓄和患者支持计划。该公司最近宣布与ARS Pharmaceuticals建立合作关系，在美国各地的零售药店以独家低折扣现金价格向neffy提供服务。

Similarly, the company launched an affordability program with Boehringer Ingelheim to provide its Humira® biosimilar (adalimumab) at a low cash price available exclusively on GoodRx. GoodRx now has over 50 pharmaceutical brands offering cash price options for consumers integrated into the GoodRx platform..

同样，该公司与勃林格殷格翰公司推出了一项可负担性计划，以低现金价格提供其Humira®生物仿制药（阿达木单抗），仅在GoodRx上提供。GoodRx目前拥有50多个制药品牌，为整合到GoodRx平台中的消费者提供现金价格选择。。

Further information can be found at www.goodrx.com/go/menopause

更多信息请访问www.goodrx.com/go/更年期

About GoodRx

关于GoodRx

GoodRx is the leading prescription savings platform in the U.S. Trusted by more than 25 million consumers and 750,000 healthcare professionals annually, GoodRx provides access to savings and affordability options for generic and brand-name medications at more than 70,000 pharmacies nationwide, as well as comprehensive healthcare research and information.

GoodRx是美国领先的处方储蓄平台。每年有2500多万消费者和750000名医疗保健专业人员信赖GoodRx。GoodRx为全国70000多家药店的仿制药和名牌药物提供储蓄和负担得起的选择，以及全面的医疗保健研究和信息。

Since 2011, GoodRx has helped consumers save over $75 billion on the cost of their prescriptions..

自2011年以来，GoodRx帮助消费者节省了超过750亿美元的处方费用。。

GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission (the “SEC”) and public conference calls and webcasts.

GoodRx定期在其投资者关系网站上发布对投资者可能重要的信息https://investors.goodrx.com.我们打算将我们的网站用作披露重大非公开信息的手段，并遵守FD法规规定的披露义务。因此，鼓励投资者和潜在投资者定期访问GoodRx的网站以获取重要信息，此外，还应关注GoodRx的新闻稿、向证券交易委员会（“SEC”）提交的文件以及公开电话会议和网络广播。

The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release..

GoodRx网站上包含的或可通过GoodRx网站访问的信息未通过引用纳入本新闻稿，也不属于本新闻稿的一部分。。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding anticipated consumer savings and accessibility; the expected benefits and value of our partnership with Pfizer and GoodRx’s other offerings; and our plans, expectations and objectives.

本新闻稿包含1995年《私人证券诉讼改革法案》所指的前瞻性声明。本新闻稿中包含的所有与历史事实无关的声明均应视为前瞻性声明，包括但不限于有关预期消费者储蓄和可及性的声明；我们与辉瑞（Pfizer）和古德克斯（GoodRx）的其他产品合作的预期收益和价值；以及我们的计划、期望和目标。

These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits; changes in medication pricing and pricing structures; our reliance on a limited number of industry participants; and the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023, and our other filings with the SEC.

这些声明既不是承诺也不是保证，但涉及已知和未知的风险、不确定性和其他重要因素，这些风险、不确定性和其他重要因素可能导致我们的实际结果、业绩或成就与前瞻性声明明示或暗示的任何未来结果、业绩或成就有实质性差异，包括但不限于与我们实现广泛市场教育和改变消费者购买习惯的能力有关的风险；药物定价和定价结构的变化；我们依赖数量有限的行业参与者；以及我们在截至2023年12月31日的10-K表年度报告以及我们向SEC提交的其他文件中，在“风险因素”标题下讨论的重要因素。

Any such forward-looking statements are based on current expectations, projections and estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change..

任何此类前瞻性声明均基于截至本新闻稿发布之日的当前预期、预测和估计。虽然我们可能会选择在未来某个时候更新此类前瞻性声明，但我们不承担任何义务，即使后续事件导致我们的观点发生变化。。